By Mark Robbins, 6 May 2026

At SugaROx, our mission has always been clear: to unlock the full potential of plant biology through precise, science-led crop biostimulants.

Our latest investment, £2.5 million from The Mosaic Company as part of our ongoing Series A funding round, marks an important step forward on that journey. This builds on their earlier support in 2025 and represents a strong endorsement of both our technology and our path to commercialisation.

This investment allows us to accelerate the field validation, registration and commercial launch of our first product and progress two other products in our pipeline from proof-of-concept to field testing.

A science-led approach to improving yield and quality

One of the longstanding challenges with traditional biostimulants, extracts from plants, algae or organic wastes, has been consistency of performance in real-world conditions. At SugaROx, we overcome this with single-molecule formulations based on proprietary versions of natural molecules that control key metabolic pathways and stress responses within plant cells.

Simply put, the molecules targeted by us can’t be delivered effectively into plant cells using conventional agricultural practices like foliar sprays due to strong polarity. Our patented ‘chemical caging’ technology enables these molecules to be absorbed by the plant and transported across cell walls and membranes – unlocking their full potential and enabling more reliable, repeatable performance in the field.

The first molecule in our pipeline, a caged version of a natural plant sugar (trehalose-6-phosphate, or T6P) targets a famine-signalling enzyme within the plant (SnRK1). By inhibiting the enzyme, we can redirect carbon and nutrients towards grain filling – improving both yield and quality.

The two other molecules in our pipeline also have well-characterised roles within plant systems, ensuring a robust scientific foundation for everything we develop.

Scaling trials and global expansion

With this latest funding, we’re expanding our field trials across key global markets, building the dataset required for regulatory approval and commercial launch in the UK, EU and US.

We’re targeting an initial UK launch between 2027 and 2028, followed by international expansion through to 2030. Our early focus will be on staple crops such as wheat and barley in Europe, and soybean and maize in North America. Work on selected high-value horticultural crops will continue alongside.

Jeff Wheeler, Vice President – Biosciences at The Mosaic Company, commented: “SugaROx is advancing a new category of precision biostimulants that aligns closely with our approach at Mosaic Biosciences, where we are building a science-backed portfolio of solutions that support the biology of plants and soil. We are pleased to support the team as they expand field validation and progress towards commercialisation.”

Looking ahead

Biostimulants are one of the fastest-growing segments in crop inputs. As growers face increasing pressure to produce more with fewer resources, the need for effective, reliable solutions has never been greater.

At SugaROx, we’re committed to delivering exactly that – precision biostimulants that work with plant biology to drive meaningful improvements in productivity and sustainability.

We’re now focused on completing our Series A round and bringing our first products to market. The opportunity ahead is significant, and this investment brings us one step closer making it a reality.

Want to know more? Follow us on LinkedIn or contact us today.